The Association of a PRECISE-DAPT Score With No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction

Selçuk, Murat; Çınar, Tufan; Şaylık, Faysal; Demiröz, Önder; Yıldırım, Ersin

doi:10.1177/00033197211010602

Cited by 12 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a retrospective analysis of 905 patients with STEMI revealed that the incidence of no-reflow was 22.7%. 36 Our result was compatible with this study.…”

Section: Discussionsupporting

confidence: 93%

The Systemic Immune-Inflammation Index Predicts Impaired Myocardial Perfusion and Short-Term Mortality in ST-Segment Elevation Myocardial Infarction Patients

et al. 2022

View full text Add to dashboard Cite

In this study, we aimed to evaluate the utility of the immune-inflammation index (SII) in estimating the no-reflow phenomenon and short-term cardiovascular prognosis in patients with ST-segment elevation myocardial infarction (STEMI). 723 consecutive patients with STEMI who underwent primary percutaneous coronary intervention (PCI) were enrolled in our study. The receiver-operating characteristics (ROC) curve was used to determine the cut-off value of SII to predict the no-reflow. The multivariate regression analysis analyzed the correlation between no-reflow and SII. The median value of SII was significantly higher in patients with no-reflow in comparison with normal reperfusion [1466 (939–2409) vs 905 (566–1379), p < .001]. The optimal threshold for SII in predicting the no-reflow phenomenon was 1036, with sensitivity and specificity of 70% and 59%, respectively. The area under the ROC curve (AUC) was 0.71 (95% CI, 0.66–0.75, p < .001). In multivariate analysis, SII ≥ 1036 value showed an independent predictive value for the no-reflow (OR = 0.51, 95% CI: 0.29–0.92, p = .02) and the 30-day cardiovascular mortality (OR = 2.37, 95% CI: 1.34–4.19, p = .003). Our results suggest that higher SII levels are independently associated with the no-reflow phenomenon and 30-day mortality in STEMI patients undergoing primary PCI.

show abstract

“…Recently, a retrospective analysis of 905 patients with STEMI revealed that the incidence of no-reflow was 22.7%. 36 Our result was compatible with this study.…”

Section: Discussionsupporting

confidence: 93%

The Systemic Immune-Inflammation Index Predicts Impaired Myocardial Perfusion and Short-Term Mortality in ST-Segment Elevation Myocardial Infarction Patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since clinical features and event rates were similar to other reports, 8,9,[15][16][17]23,24 we believe that our results might be representative and useful in clinical practice beyond the single-center studies previously reported. 16,[25][26][27][28][29][30] Early risk stratification and structured discharge planning of STEMI patients have gained interest in the last years 12,13 and, moreover, through the COVID-19 pandemic. 6 Adoption of this treatment strategy could reduce hospital costs, resource utilization, and enhance patient satisfaction without affecting outcome.…”

Section: Discussionmentioning

confidence: 99%

Applicability of the Zwolle score for selection of very high-risk ST-elevation myocardial infarction patients treated with primary angioplasty

et al. 2022

View full text Add to dashboard Cite

The Zwolle risk score was designed to stratify in-hospital mortality risk of ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (pPCI) and for decision-making in the unit where patients are admitted. We assessed the accuracy of Zwolle risk score for in-hospital mortality estimation compared with the GRACE score in all patients (n = 4446) admitted for STEMI in 3 university hospitals. Only one fourth of the patients were classified as high-risk by the Zwolle risk score vs 60% by the GRACE score. In-hospital mortality was 10.6%. A statistically significant increase in in-hospital mortality, adjusted by age, gender, and revascularization, was observed with both scores. The assessment of the optimal cut-off points verified the accuracy of Zwolle score ≥4 as optimal threshold for high-risk categorization. In contrast, GRACE score ≥140 had very low specificity as well as percentage of patients correctly classified; GRACE score ≥175 was fairly better. The reclassification index of the Zwolle score after applying the GRACE score was 35.5%. Selection of high-risk STEMI patients treated with pPCI based on the Zwolle risk score has higher specificity than the GRACE score and might be useful in clinical practice.

show abstract

“…Coronary no-re ow is a particular complication that should be wacth out in PCI treatment [5] . Nore ow inhibits ow exchange in the myocardial ischemic zone, prevents healing of the myocardial necrotic zone, delays ventricular remodeling, increases the incidence of heart failure [6] , and is an independent predictor of rehospitalization, malignant arrhythmias, and heart failure, recurrent myocardial infarction, and cardiovascular death in patients after PCI [7] .…”

Section: Discussionmentioning

confidence: 99%

“…(3) Underwent PCI, including drug-eluting stenting, bioresorbable stenting, coronary drug balloon dilatation. (4) No-re ow during PCI, de ned as coronary ow TIMI grade 0-2 after coronary balloon dilation or coronary stenting [4] . Exclusion criteria: those with impaired antegrade coronary artery ow due to in situ thrombosis,dissection, severe spasm, and distal embolism.This approach had hospital ethics committee approval and patient ' s informed consent.…”

Section: Study Populationmentioning

confidence: 99%

Effectiveness of Intra-Coronary Injection of Sodium Nitroprusside for the Treatment of Coronary No-Reflow through Punctured Coronary Balloon

Lai¹,

Wang²

2022

IJPS

View full text Add to dashboard Cite

BackgroundRapid restoration of TIMI 3 on case of no-re ow during PCI is imperative. Application of punctured coronary balloon intracoronary injection of sodium nitroprusside is a prompt, safe and effective method. ObjectiveTo investigate the effectiveness of intracoronary injection of Sodium Nitroprusside via punctured coronary balloon in the treatment of no-re ow in coronary artery.Methods: We retrospectively analyzed 76 patients treated with intracoronary injection of Sodium Nitroprusside via punctured coronary balloon for coronary no-re ow. ResultsAll 76 patients successfully completed intracoronary injection of Sodium Nitroprusside, with the improvement of no-re ow in coronary artery to TIMI grade III in 74 patients. There were two complications occurred in the early application of this technique: one was a punctured coronary balloon fracture left in the distal coronary artery, and the other was a di cult pullbacking of the punctured coronary balloon catheter. After improving the application method, no more complication case occurred in 67 cases afterward, and no complications such as coronary guide wire pulled out of the coronary artery, coronary artery dissection, coronary artery perforation, and coronary artery air embolism occurred. ConclusionCoronary no-re ow treatment with intracoronary injection of Sodium Nitroprusside via punctured coronary balloon is safe and effective when properly applied.

show abstract

The Association of a PRECISE-DAPT Score With No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction

Cited by 12 publications

References 19 publications

The Systemic Immune-Inflammation Index Predicts Impaired Myocardial Perfusion and Short-Term Mortality in ST-Segment Elevation Myocardial Infarction Patients

The Systemic Immune-Inflammation Index Predicts Impaired Myocardial Perfusion and Short-Term Mortality in ST-Segment Elevation Myocardial Infarction Patients

Applicability of the Zwolle score for selection of very high-risk ST-elevation myocardial infarction patients treated with primary angioplasty

Effectiveness of Intra-Coronary Injection of Sodium Nitroprusside for the Treatment of Coronary No-Reflow through Punctured Coronary Balloon

Contact Info

Product

Resources

About